



HAL
open science

The Clinical Effectiveness of Chokeberry: A Systematic Review

Cosima Amélie Chrubasik, George Li, Sigrun Chrubasik

► **To cite this version:**

Cosima Amélie Chrubasik, George Li, Sigrun Chrubasik. The Clinical Effectiveness of Chokeberry: A Systematic Review. *Phytotherapy Research*, 2010, 10.1002/ptr.3226 . hal-00552432

HAL Id: hal-00552432

<https://hal.science/hal-00552432v1>

Submitted on 6 Jan 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The Clinical Effectiveness of Chokeberry: A Systematic Review

Journal:	<i>Phytotherapy Research</i>
Manuscript ID:	PTR-10-0356
Wiley - Manuscript type:	Review
Date Submitted by the Author:	31-Mar-2010
Complete List of Authors:	Chrubasik, Cosima; Braun School of Public Health, The Hebrew University-Hadassah Medical School Li, George; Sydney University, Herbal Medicines Research and Education Center Chrubasik, Sigrun; Institute of Forensic Medicine, University of Freiburg im Breisgau
Keyword:	Chokeberry, Aronia melanocarpa, systematic review, clinical trials



Review

1

The Clinical Effectiveness of Chokeberry: A Systematic Review**C. Chrubasik¹, G. Li², S. Chrubasik^{2,3}**

¹Braun School of Public Health, Hadassah Medical Center, Hebrew University, Jerusalem, Israel

²Herbal Medicines Research and Education Centre, Faculty of Pharmacy, University of Sydney, NSW 2006, Australia

³Institute of Forensic Medicine, University of Freiburg, Freiburg, Germany

Correspondence and requests for reprints to

Dr. Cosima Chrubasik

Braun School of Public Health

The Hebrew University-Hadassah Medical School

POB 12272, Jerusalem, 91120

Israel

[Email: chrubasik@gmail.com](mailto:chrubasik@gmail.com)

Abstract

Products derived from the black chokeberry, *Aronia melanocarpa*, are claimed to be beneficial in disorders or diseases associated with oxidative stress. The claims are based on evidence from *in vitro* studies and animal experiments. The active principle - a mixture of procyanidins, anthocyanins and phenolic acids - constitutes one of the most potent natural antioxidants. We carried out a systematic review of the quality of the clinical trials on chokeberry products that had been published up to December 2009, and used conventionally established criteria to assess the strength of the evidence for their clinical effectiveness. Thirteen studies were identified. The quality of most of the trials and, correspondingly, the evidence of effectiveness for *Aronia* products is poor. Though laboratory and clinical data indicate that chokeberry products may well be useful as “functional food” for disorders or diseases related to oxidative stress, these promising indications need to be confirmed in more rigorous studies before putative therapeutic uses can be confidently recommended for chokeberry products.

Key words

Chokeberry, *Aronia melanocarpa*, systematic review, clinical trials, anti-oxidative effect

INTRODUCTION

The black chokeberry, *Aronia melanocarpa* (Family: Rosaceae) is native to North America and Canada and was introduced into Europe about a century ago. Because of the astringent taste of the raw berries and their smell of bitter-almonds, pure *Aronia* products are not particularly popular, although they have been documented as a “functional food” in Russia since the 1940s. Chokeberry juice has been used primarily for blending with other juices or in the preparation of syrups, jellies, teas, liqueurs, spirits and fruit wine. The interest in *Aronia* products has recently increased, not only because of the putative health-promoting effects of *Aronia*, but also because the plant is pest-resistant and easy to cultivate (http://opus.haw-hamburg.de/volltexte/2008/513/pdf/med_y_210.pdf). Laboratory reports of potentially useful activities began to appear in the mid 1990s, and these have been accompanied since 2000 by a modest number of reports of its use in a variety of clinical settings.

Chokeberries have a greater content of phenolic constituents than most of the other black berries (Kahkönen et al., 2001, Wu et al., 2004). These comprise procyanidins, anthocyanins and phenolic acids, and the amounts reflect antioxidative potency in laboratory testing (Zheng and Wang, 2003). Procyanidins and some anthocyanins may also form complexes with free iron and copper, which catalyse free-radical reactions and contribute to the reduction in pro-oxidative activity seen with *Aronia* products (Hider et al., 2001). Popular health claims for *Aronia* products are that they: (i) combat heart disease and other cardiovascular problems, (ii) mitigate hypertension, (iii) maintain a healthy urinary tract, (iv) fight against bacteria and viruses, (v) strengthen memory, (vi) aid digestion and (vii) help to decrease the amount of cholesterol carried as Low Density Lipoproteins (LDP) (www.associatedcontent.com/article/870111/10_benefits_of_aronia_berry.html?cat=51). Additional claims by association have been made in diabetes and arthritis (www.doverpost.com/lifestyle/x124604982/Studies-show-aronia-berries-may-be-full-of-

4

1
2 health-benefits), as well as in cancer (<http://hubpages.com/hub/aronia>). These claims are
3
4 primarily based on research with other black berry products or isolated anthocyanins (Zafra-
5
6 Stone et al., 2007) or are transferred from *in vitro* and experimental studies with chokeberry
7
8 preparations (Kulling et al., 2008).
9

10 The aim of this systematic review is to evaluate the current *clinical* evidence for effectiveness
11
12 of chokeberry preparations.
13
14

16 METHODS

17
18 We searched several electronic databases: Medline/ OVID, Silverplatter, and CENTRAL
19
20 from 1950 up to December 2009, using some or all of the search terms: chokeberry, *Aronia*,
21
22 *Aronia melanocarpa* and searched by hand for publications not stored electronically (eg:
23
24 theses, webpages). Two authors (CC and SC) extracted the data independently and evaluated
25
26 the quality of the studies and the strength of the evidence of clinical effectiveness using the
27
28 same criteria as in previous reviews (Chrubasik et al., 2004, Gagnier et al., 2004, Chrubasik et
29
30 al., 2006, 2007a,b, 2008, Vlachojannis et al., 2009, 2010a,b).
31

32 Briefly, the assessment of quality was based on “yes” or “no” answers to the following
33
34 questions (to the extent that they were applicable in the context of each study):
35

36 Was or were -

- 37
38 (i) patients included on the basis of specified eligibility criteria;
39
40 (ii) randomization appropriate;
41
42 (iii) treatment allocation concealed;
43
44 (iv) baseline values of the groups similar
45
46 (v) outcome measures and control interventions explicitly described;
47
48 (vi) co-interventions comparable;
49
50 (vii) outcome measures relevant;
51
52 (viii) adverse events fully described;
53
54
55
56
57
58
59
60

- 1
2 (ix) attrition of patients from the study (the “drop-outs”) fully described;
3
4 (x) sample size based on *a priori* power calculation;
5
6 (xi) in the event of attrition of patients during the study, analysis by intention-to-treat;
7
8 (xii) point estimates and measures of variability presented for the primary outcome measure;
9
10 (xiii) studies undertaken over an appropriate time-course to demonstrate the putative effect

11
12 Clearly, for some studies, particularly simple observational studies, some of the questions are
13
14 not applicable but the inability to supply a “yes” answer is, in itself, a marker of “absence of
15
16 quality” in systematic reviews of this sort.
17

18 Disagreements between the assessors over these deliberately simplified questions were few
19
20 (arising mostly from lack of transparency in describing methods) and were resolved after
21
22 discussion. Adding up the “yes” answers applicable to each study gave it a Total Score (TS)
23
24 out of a maximum of 13. The distribution of Total scores for the studies in the review is one
25
26 way to indicate the strength of evidence of effectiveness from a group of individual studies.
27
28 Early in the history of the clinical investigation of a particular product, most of the studies
29
30 will be “exploratory” in that they determine the conditions, study design, and sample size
31
32 needed in planning to maximise the chances of demonstrating useful clinical effects in later
33
34 “confirmatory” studies.
35

36 A conventional way of assessing evidence of clinical effectiveness from a more mature body
37
38 of work is to define the evidence as “strong”, “medium” or “weak”, according to the
39
40 following criteria: (i) “strong” – pooling of data from at least 2 confirmatory studies
41
42 demonstrating a clinically relevant effect; (ii) “moderate” – consistent findings from one
43
44 confirmatory study with a clinically relevant effect, multiple exploratory studies of high
45
46 internal validity, or both; (iii) poor - multiple exploratory studies of low internal validity or a
47
48 single study of high internal validity.
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Thirteen clinical trials were identified. They have been assigned a number from 1 to 13 in chronological order, to facilitate reference between the tables and the text. Table 1 gives some characteristics of the publications in which the studies appeared, and the general setting. Nine papers/abstracts were in English and the remaining 4 in Polish. In 8 papers (numbers 4,5,7-11,13), the setting was either the “metabolic syndrome (papers 7,9,11) - a constellation of features under the general headings: abdominal obesity, atherogenic dyslipidaemia, hypertension, insulin resistance, and prothrombotic and pro-inflammatory state - or conditions presenting with a single or limited selection of those features (papers 4, 5, 8,10, 13). Three of the remaining 5 studies (papers 1-3) investigated effects of *Aronia* in other conditions with increased oxidative stress, and the other 2 (papers 6 and 12) were of the effects of *Aronia* on the antioxidant capacity in healthy volunteers (Table 1).

Table 2 gives some indication of how the studies were carried out. Five studies (papers 5,7,10,12,13) had only one group, 2 being simple observational studies of effects of giving an *Aronia* product (paper 5 and 7), and the rest incorporating a formal, single or double crossover, either to a placebo or no treatment (10,12,13). The remaining studies were comparisons between an “*Aronia*” group (receiving an *Aronia* product) and either a “Placebo” group (receiving a placebo) or a “Control” group of patients receiving nothing (papers 3,4,6,8,9,11) or healthy subjects receiving nothing (1,2).

In 7 studies (papers 1,2,5,7-9, 11) the *Aronia* product was Aronox^R, prepared from the berries, not by a solvent extraction, but by purification on chromatographic bed, drying and vaporization (annaskoc@ak.am.wroc.pl), and standardised in 100 mg tablets each containing 15 mg of anthocyanins. In the remaining papers, the *Aronia* product consisted of juices with varying anthocyanin contents (Table 1). We tried unsuccessfully to contact Dr. Naruszewicz by phone and email (marek.naruszewicz@wum.edu.pl), in an attempt to clarify how and why

1
2 he appears to have used three 85 mg tablets of Aronox^R per day as his study medication -
3
4 although Aronox tablets contain a 100 mg dose of dried juice.

5
6 The duration of the studies ranged from 2 hours to 3 months, with most lasting between 4 and
7
8 8 weeks. In almost all of the studies, there was a striking multiplicity in the measurements
9
10 undertaken as potential outcome measures – indicating a strong “exploratory” trust to those
11
12 studies. The use of the *Aronia* product was associated, in every study, with a favourable
13
14 change in at least one or more of the measurements that had been undertaken (Table 3).
15
16

17
18 Table 4 shows the responses to the questions by which the quality of each study was assessed.
19
20 All scored at least 4 “yeses”, for questions (i), (v), (vii) and (xiii) but, although all outcomes
21
22 were explicitly described and relevant to the condition under study, there is no transparency
23
24 as to whether any single outcome had been pre-specified for the purposes of hypothesis
25
26 testing and *a priori* planning of sample size as would be required for a study to be considered
27
28 “confirmatory” rather than “exploratory” as defined in the Methods. Thus, although the
29
30 collection of 10 studies centring on the metabolic syndrome and aspects thereof produced
31
32 generally consistent favourable results for the chosen *Aronia* product, the collection does not
33
34 include even a single “confirmatory” study, so that the overall strength of evidence, in even
35
36 this reasonably coherent body of work, must be classified as “poor” by the criteria outlined in
37
38 the Methods section. Besides the lack of transparency over advance stipulation of a critical
39
40 outcome measure, only one study (paper 12) gave any adequate account of adverse events and
41
42 only one gave adequate account of attrition (paper 8, in which the attrition was zero!).
43
44 Attrition needs to be considered in relation to whether the results should be analysed *per*
45
46 *protocol* or by intention to treat). Nonetheless, an encouraging feature of Table 3 is the trend
47
48 towards improved study quality over the 9 years for which the *Aronia* products have been
49
50 studied.
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Although the limited body of work up to December 2009 presents evidence of clinical effectiveness which must be classified as “poor” by conventional criteria, it is by no means unpromising. However, for the products to gain the acceptance that they may well deserve, a new generation of “confirmatory” studies needs to be planned and undertaken. The evidence from laboratory investigations (reviewed recently, for example, by (Kullig and Rawel, 2008), as well as the clinical studies covered in this review provide potentially valuable pointers for the planning process. The laboratory investigations consist of product stability studies and studies, in animal models and cell lines of various areas of potential benefit and toxicity, and dose finding.

Product stability studies. The rate of degradation of anthocyanins is affected by type of anthocyanidin, the amount of glycosylated sugar and the care taken to reduce contact with air (specifically oxygen) during preparation before packaging in bottles or cartons (Kaack and Austed, 1998), and during storage (the degradation of total anthocyanins has been shown to be 22% faster in cartons, for example, than in glass bottles (Trost et al., 2008). Vitamin C can reduce the oxidative degradation of the anthocyanins (Kaack and Austed, 1998) and the near black anthocyanidin-containing juices are often presented as dilutions other fruit juice, e.g. lemon juice. The in vitro antioxidant activity of a lemon juice mixture was twice as high when pure lemon juice was enriched with 5% of *Aronia* concentrate (González-Molina et al., 2008). Dilutions of *Aronia* juice in lemon juice have an attractive red colour that depends on a mixture of glycosylated and non-glycosylated anthocyanins (aglycones). The ranking order of individual non-glycosylated anthocyanins in a blueberry-aronia nectar (from the most to least stable) was as follows: cyanidin > peonidin > petunidin > malvidin = delphinidin. For the glycosylated anthocyanins, the sugar with which the anthocyanidin is glycosylated makes a difference, degradation rate being least with glucose

1
2 as the glycosylating sugar, intermediate with galactose and most with arabinose (Troost et al.,
3 2008). In dilutions of Aronia concentrate 2.5% and 5% in a lemon juice, the red colour was
4 retained over 60 days despite a degradation of more than 90% in the antioxidative capacities
5 supplied by the anthocyanidins - so colour is no guide to potential effectiveness (González-
6 Molina et al., 2008).

7
8
9
10
11
12 Temperature is important. Keeping *Aronia* juice concentrate for 8 hours at 60° C° resulted in
13 a decrease of the polyphenol and anthocyanidin content by 22% and 35%, respectively, with
14 an associated decrease in antioxidant activity of 56%. Thus the prolonged drying processes
15 used in the manufacture of some *Aronia* berry products may be better avoided
16 (Kasparaviciene and Briedis, 2003; Kähkönen et al., 2001). Freeze- drying may be a better
17 option – or, depending on the cost of the raw materials, it may be cheaper simply to increase
18 the dose of a product such as Aronox^R. Whatever may be the case, there seems to be some
19 scope for increasing the content of the putative active principle in future *Aronia* products.
20
21
22
23
24
25
26
27
28
29
30

31 **Laboratory studies indicating potential benefits of *Aronia* or anthocyanins**

32
33 The earliest documented laboratory demonstration of a potentially useful action of *Aronia* was
34 an anti-inflammatory effect shown in 1994 by Borissova and co-workers. *Aronia*
35 anthocyanins were more effective than rutin in suppressing inflammation in the rat paw
36 oedema test. More recently, a potent anti-inflammatory effect of a proprietary extract of
37 *Aronia* was demonstrated in endotoxin-induced uveitis in rats (Ohgami et al., 2005). After 24
38 hours, the number of inflammatory cells, the protein concentrations, and the levels of NO,
39 PGE2, and TNF-alpha in aqueous humour from both eyes were dose-dependently decreased.
40
41 The anti-inflammatory effect of 100 mg of *Aronia* extract was as strong as that of 10 mg of
42 prednisolone and stronger than that of either anthocyanin or quercetin, another component of
43 the extract, when given alone. The same extract also dose-dependently suppressed LPS-
44 induced nitric oxide synthase and COX-2 protein expressions in a mouse macrophage cell
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

10

1
2 line, indicating that it acts in pathways that involve several inflammatory mediators (Ohgami
3
4 et al., 2005).

5
6
7
8 In 1995, Niedworok et al described protection against damage from cyclophosphamide” and
9
10 radiation disease (1995 theses quoted in Niedworok’s review;
11
12 bdb.trzcianka.com.pl/oferujemy/Aronox badania/ANG/Table I-25_eng.pdf).

13
14 Another early demonstration of potential benefit was by Atanasova-Goranova et al. in 1997.
15
16 Their study in rats showed a hepatoprotective effect: *Aronia* nectar (fruit juice and pulp from
17
18 the black chokeberry) inhibited nitrosamine production induced by aminopyrin and sodium
19
20 nitrite in rats with a concomitant reduction in organic liver damage. *Aronia* juice also showed
21
22 a hepatoprotective effect when given as a pre-treatment in a rat model of hepatotoxicity
23
24 (Valcheva-Kuzmanova et al., 2004 and 2006). The juice prevented the carbon tetrachloride-
25
26 induced increase in transaminase activities, and also the elevation of plasma and liver
27
28 malondialdehyde.
29

30
31
32 Since these early demonstration of tissue and cellular, there have been many others. Two
33
34 studies revealed some antimutagenic potential of *Aronia* extract or its anthocyanin ingredients
35
36 (Gasiorowski et al., 1997; Gasiorowski and Brokos, 2001). Rats treated with the colonic
37
38 carcinogen “azoxymethane”and fed a diet with *Aronia* extract (385 mg of anthocyanins and
39
40 1645 mg of total phenolics per g of diet) had fewer foci of aberrant colonic cryptscolonic
41
42 aberrant crypt foci and less proliferation of colonic cells, suggesting that anthocyanin-rich
43
44 *aronia* extracts may offer some protect against colonic cancer (Lala et al., 2006). However,
45
46 although force feeding of rats with 8 ml/kg of chokeberry juice for 28 days was apparently
47
48 harmless, doing so in combination with the chemical carcinogen, N-nitrosodiethylamine,
49
50 caused more toxicity and DNA damage than the carcinogen alone (Krajka-Kuźniak et al.,
51
52 2009).
53
54
55
56
57
58
59
60

1
2
3
4 Isolated anthocyanins from *Aronia* were also shown to reduce pancreatic swelling in rats
5 with PAF- or ceruleine-induced pancreatitis, with a concomitant decrease in lipid
6 peroxidation and adenosine deaminase activity (Jankowski et al., 2000). Generally “anti-
7 diabetic” effects have been shown in various models of diabetes and hyperlipidemia
8 (mimicking the metabolic syndrome) in rats. Large doses of *Aronia* juice (10 or 20 ml/kg)
9 given for 6 weeks significantly reduced elevated plasma glucose and triglycerides in rats with
10 streptozotocin-induced diabetes and diet-induced hyperlipidemia, (Valcheva-Kuzmanova
11 et al., 2007a). Given for only 30 days they reduced plasma total cholesterol, LDL-cholesterol
12 and triglycerides (Valcheva-Kuzmanova et al., 2007b). In a similar rat model of pancreatic
13 dysfunction, benefits have been demonstrated from feeding for 4 weeks with 0.2% chokeberry
14 extract (714 mg/g total polyphenols, 57% anthocyanin glycosides; Agropharm) (Jurgoński et
15 al., 2008).
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 Matsumoto et al., 2004 demonstrated a gastro-protective effect of a methanolic extract of
31 *Aronia* (DER 1:10) that as effective as that of quercetin and was caused by the red pigment
32 fraction of the extract. In a rat model in which gastric ulcers were induced by indomethacin, a
33 significant reduction of the depth and severity of mucosal lesions was found when *Aronia*
34 juice was given concomitantly with the indomethacin (Valcheva-Kuzmanova et al., 2005).
35 Isolated *Aronia* anthocyanins have also been shown in rats to mitigate the effects of poisoning
36 by lead (Kowalczyk et al., 2002) and cadmium (Kowalczyk et al., 2005).
37
38
39
40
41
42
43
44
45
46

47 Several in-vitro studies, one open study in chimpanzes and two exploratory studies in humans
48 have suggested that an aqueous elderberry extract may have a place in the treatment of viral
49 infections including the pandemic ones (Vlachijannis et al., 2010). Black chokeberries contain
50 even more anthocyanins than do elderberries (Wu et al. 2004), and an *in vitro* study has
51
52
53
54
55
56
57
58
59
60

12

1
2 shown that *Aronia* juice inhibited the reproduction of *Influenza* virus in its initial stages.

3
4 Thus, proprietary standardized *Aronia* products may possibly have some use as anti-influenza
5
6 preparations. (http://www.antibiotikamonitor.at/34_03/34_03_1_04.htm).

7
8
9
10 Such an extraordinary multiplicity of effects claimed for *Aronia* has suggested to many
11
12 researchers and practitioners that the *Aronia* products affect very basic cellular processes that
13
14 are common to its many putative effects – namely effects that reduce the pathological
15
16 generation of oxygen free radicals and/or promote scavenging of oxygen free radicals
17
18 (Kulling et al., 2008).

19
20
21
22 **Safety:** The Polish company Agropharm in Lodz has some unpublished data showing that
23
24 intragastric administration of up to 5 g/kg of *Aronia* anthocyanins was not associated with any
25
26 toxic symptoms in mice. Likewise, giving 10 mg/kg of anthocyanins for 6 weeks was well
27
28 tolerated and the internal organs did not show any histological changes
29
30
31 (http://bdb.trzcianka.com.pl/oferujemy/Aronox%20badania/ANG/Table%20I-25_eng.pdf).

32
33 Nonetheless, the observations of (Krajka-Kuźniak et al., 2009) indicate that some attention
34
35 needs to be given to the possibility that *Aronia* products and related substances may act
36
37 synergistically with other foodstuffs, medicines, poisons, chemotherapeutic agents, etc., that
38
39 may be relevant in patients for whom in future *Aronia* products might otherwise be indicated.
40
41

42 43 **Pointers to planning “confirmatory” clinical studies**

44
45 **Setting:** The metabolic syndrome and related disorders seem to be a promising target
46
47 population to be studied, in that the conditions are prevalent, and increasingly so. Finding
48
49 suitable subjects to study will be relatively easy and any demonstrated benefits are likely to
50
51 reduce, not only the morbidity and mortality of the conditions, but also their enormous
52
53 financial effects. The same might be said of endemic viral diseases such as influenza.
54
55
56
57
58
59
60

1
2
3 **Dose:** Doses do of course need to be tailored to the target populations to be investigated, but
4 current empirical experience suggests that the daily dose of *Aronia* product should contain
5
6 300 - 600 mg of anthocyanins – considerably more than in the clinical studies reviewed here
7
8 (http://bdb.trzcianka.com.pl/oferujemy/Aronox%20badania/ANG/Table%20I-25_eng.pdf). If
9
10 the doses used in animal studies are extrapolated to humans, the daily dose would correspond
11
12 to an anthocyanin content of 1600 to 3000 mg contained in about 700 -1400 ml juice per day
13
14 (see below). Considerations of dose need to take into account considerations of how different
15
16 *Aronia* products are manufactured and stored (see above – Product stability)

17
18 **Adverse reactions:** Considerations of dose also need to be tempered by considerations of
19
20 possible adverse interactions with co-medications (see above), and for affects that may
21
22 conceivably not have been studied fully in animals. Although no adverse events were reported
23
24 in any of the clinical studies reviewed, squeezed *Aronia* juice may have mild diuretic and
25
26 laxative effects from its potassium content and sorbitol-related laxative effects. Long-term use
27
28 of *Aronia* preparations may conceivably cause anaemia because of the iron-chelating effect of
29
30 anthocyanins. Like other polyphenol-containing products, *Aronia* juice or concentrate can
31
32 also cause superficial staining of the teeth stain (Shellis et al., 2005). As with almost any
33
34 product containing molecules of sufficient size, hypersensitivity may occur, albeit rarely.

Formatiert: Nicht Hervorheben

35
36 It is, of course mandatory that, for any adverse reactions that occur during any studies, a full
37
38 description is provided, and a formal consideration of the likelihood that it is causally related
39
40 to the product being studied. If subjects fail to complete the study because of adverse effects
41
42 or any other reason, consideration of the possible effects of that attrition must be allowed for
43
44 by comparing intention to treat and per protocol analyses of the results.

45
46
47 **Outcome measures:** Those used in the clinical trials reviewed to be reliable and relevant to
48
49 improved well-being.

50
51 **Duration:** Short and medium term studies of biochemical and cytological measurements are
52
53 needed as well as simple clinical measurements such as body weight and arterial blood
54
55
56
57
58
59
60

14

1
2 pressure (as in Table 2) which are indications of potential benefit on terms of risk reduction.

3
4 Longer term studies are also required to determine whether the potential risk reduction is
5
6 translatable into better clinical outcomes from disease, improved life expectancies and greater
7
8 confidence that the potential benefits are not offset by toxicity in the longer term

9
10 (www.fda.gov/cder/guidance/index.htm,
11
12 www.emea.europa.eu/pdfs/human/ich/030095en.pdf).

Feldfunktion geändert

13
14
15
16 In conclusion, there is appreciable experimental evidence of the effectiveness of *Aronia*
17
18 products in an extraordinary range of pathological conditions in which the underlying damage
19
20 is probably mediated by uncontrolled oxidative processes. The current evidence of
21
22 effectiveness in several clinical contexts is promising, but does not yet meet the accepted
23
24 standards that would secure them an indisputable place in therapy. Fortunately, there are
25
26 several promising avenues of investigation that may be pursued to remedy the present
27
28 shortcomings.
29

30 31 32 **References**

33
34 Atanasova-Goranova VK, Dimova PI, Pevicharova GT. 1997. Effect of food products on
35
36 endogenous generation of N-nitrosamines in rats. *Br J Nutr* **78**:335-45.

37
38
39
40 Borissova P, Valcheva S, Belcheva A. 1994. Antiinflammatory effect of flavonoids in the
41
42 natural juice from *Aronia melanocarpa*, rutin and rutin-magnesium complex on an
43
44 experimental model of inflammation induced by histamine and serotonin. *Acta Physiol*
45
46 *Pharmacol Bulg* **20**:25-30.
47

48
49
50
51 Broncel M, Koziróg-Kołacińska M, Andrykowski G, Duchnowicz P, Koter-Michalak M,
52
53 Owczarczyk A, Chojnowska-Jezierska J. 2007. [Effect of anthocyanins from *Aronia*
54
55
56
57
58
59
60

1
2 melanocarpa on blood pressure, concentration of endothelin-1 and lipids in patients with
3
4 metabolic syndrome]. *Pol Merkur Lekarski* **3**:116-9.

5
6
7
8 Chrubasik S, Conradt C, Roufogalis B. 2004. Effectiveness of *Harpagophytum* extracts and
9
10 clinical efficacy. *Phytotherapy Res* **18**: 187-9.

11
12
13
14 Chrubasik C, Duke RK, Chrubasik S. 2006. The evidence for clinical efficacy of rose hip and
15
16 seed: a systematic review. *Phytother Res* **20**:1-3.

17
18
19
20 Chrubasik JE, Roufogalis BD, Wagner H, Chrubasik S. 2007a. A comprehensive review on
21
22 nettle effect and efficacy profiles. Part I: *Herba urticae*. *Phytomedicine* **14**:423-35.

23
24
25
26 Chrubasik JE, Roufogalis BD, Wagner H, Chrubasik S. 2007b. A comprehensive review on
27
28 nettle effect and efficacy profiles. Part II: *Urticae radix*. *Phytomedicine* **14**:568-79.

29
30
31
32 Chrubasik C, Roufogalis B, Müller-Ladner U, Chrubasik S. 2008. A systematic review on the
33
34 *Rosa canina* effect and efficacy profiles. *Phytother Res* **22**:725-33.

35
36
37
38 Gagnier JJ, Chrubasik S, Manheimer E. 2004. *Harpagophytum procumbens* for osteoarthritis
39
40 and low back pain: A systematic review. *BMC Complement Altern Med* **4**:13.

41
42
43
44 Gasiorowski K, Szyba K, Brokos B, Kołaczyńska B, Jankowiak-Włodarczyk M, Oszmiański
45
46 J. 1997. Antimutagenic activity of anthocyanins isolated from *Aronia melanocarpa* fruits.
47
48 *Cancer Lett* **119**:37-46.
49
50

1
2 Gasiorowski K, Brokos B. 2001. DNA repair of hydrogen peroxide-induced damage in
3 human lymphocytes in the presence of four antimutagens. A study with alkaline single cell
4 gel electrophoresis (comet assay). *Cell Mol Biol Lett* **6**:897-911.
5
6
7

8
9
10 González-Molina E, Moreno DA, García-Viguera C. 2008. *Aronia*-enriched lemon juice: a
11 new highly antioxidant beverage. *J Agric Food Chem* **56**:11327-33.
12
13
14

15
16 Hider RC, Liu ZD, Khodr HH. 2001. Metal chelating of polyphenols In: Packer L, editor.
17 *Methods in enzymology, flavonoids and other polyphenols*. Vol. 335, San Diego: Academic
18 Press:190–203.
19
20
21

22
23
24 Jankowski A, Jankowska B, Niedworok J. 2000. [The influence of *Aronia melanocarpa* in
25 experimental pancreatitis]. *Pol Merkur Lekarski* **8**:395-8.
26
27
28

29
30 Jensen GS, Wu X, Patterson KM, Barnes J, Carter SG, Scherwitz L, Beaman R, Endres JR,
31 Schauss AG. 2008. In vitro and in vivo antioxidant and anti-inflammatory capacities of an
32 antioxidant-rich fruit and berry juice blend. Results of a pilot and randomized, double-blind,
33 placebo-controlled, cross-over study. *J Agricult Food Chem* **56**:8326-333.
34
35
36
37

38
39
40 Jurgoński A, Juśkiewicz J, Zduńczyk Z. 2008. Ingestion of black chokeberry fruit extract
41 leads to intestinal and systemic changes in a rat model of prediabetes and hyperlipidemia.
42 *Plant Foods Hum Nutr* **63**:176-82.
43
44
45

46
47
48 Kaack K, Austedt T. Interaction of vitamin C and flavonoids in elderberry (*Sambucus nigra*
49 L.) during juice processing. *Plant Foods Human Nutr* 1998;52:187-198.
50
51
52
53
54
55
56
57
58
59
60

1
2 Kähkönen MP, Hopia AI, Heinonen M. 2001. Berry phenolics and their antioxidant activity. J
3 Agric Food Chem **49**:4076-82.
4
5

6
7
8 Kasparaviciene G, Briedis V. 2003. [Stability and antioxidant activity of black currant and
9 black aronia berry juices]. Medicina (Kaunas) **39** Suppl 2:65-9.
10
11

12
13
14 Kowalczyk E, Jankowski A, Niedworok J, Smigielski J, Jankowska B. 2002
15 [The effect of anthocyanins from *Aronia melanocarpa* and acetylcysteine on selected after-
16 effects of lead acetate poisoning]. Pol Merkur Lekarski **12**:221-3.
17
18
19

20
21
22 Kowalczyk E, Kopff A, Fijałkowski P, Kopff M, Niedworok J, Błaszczuk J, Kedziora J,
23 Tyślerowicz P. 2003. Effect of anthocyanins on selected biochemical parameters in rats
24 exposed to cadmium. Acta Biochim Pol **50**:543-8.
25
26
27

28
29
30 Kowalczyk E, Fijałkowski P, Kura M, Krzesiński P, Błaszczuk J, Kowalski J, Smigielski J,
31 Rutkowski M, Kopff M. 2005. [The influence of anthocyanins from *Aronia melanocarpa* on
32 selected parameters of oxidative stress and microelements contents in men with
33 hypercholesterolemia]. Pol Merkur Lekarski **19**:651-3.
34
35
36
37

38
39
40 Krajka-Kuźniak V, Szafer H, Ignatowicz E, Adamska T, Oszmiański J, Baer-Dubowska W.
41 2009. Effect of Chokeberry (*Aronia melanocarpa*) juice on the metabolic activation and
42 detoxication of carcinogenic N-nitrosodiethylamine in rat liver. J Agric Food Chem **57**:5071-
43 7.
44
45
46
47

48
49
50
51 Kulling SE, Rawel HM. 2008. Chokeberry (*Aronia melanocarpa*) - A review on the
52 characteristic components and potential health effects. Planta Med. **74**:1625-34.
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Lala G, Malik M, Zhao C, He J, Kwon Y, Giusti MM, Magnuson BA.2006. Anthocyanin-rich extracts inhibit multiple biomarkers of colon cancer in rats. *Nutr Cancer* **54**:84-93.

Matsumoto M, Hara H, Chiji H, Kasai T. 2004. Gastroprotective effect of red pigments in black chokeberry fruit (*Aronia melanocarpa* Elliot) on acute gastric hemorrhagic lesions in rats. *J Agric Food Chem* **52**:2226-9.

Naruszewicz M, Laniewska I, Millo B, Dłuzniewski M. 2007. Combination therapy of statin with flavonoids rich extract from chokeberry fruits enhanced reduction in cardiovascular risk markers in patients after myocardial infarction (MI). *Atherosclerosis* **194**:e179-84.

Naruszewicz M, Daniewski M, Laniewska I, Pikto-Pietkiewicz W, Millo B, Zapolska-Downar D. 2003. Effect of anthocyanins from chokeberry (*Aronia melanocarpa*) on blood pressure, inflammatory mediators and cell adhesion molecules in patients with a history of myocardial infarction (MI). *Atherosclerosis Suppl* **4**: 143.

Ohgami K, Ilieva I, Shiratori K, Koyama Y, Jin XH, Yoshida K, Kase S, Kitaichi N, Suzuki Y, Tanaka T, Ohno S. 2005. Anti-inflammatory effects of *aronia* extract on rat endotoxin-induced uveitis. *Invest Ophthalmol Vis Sci* **46**:275-81.

Pawlowicz, P. Wilczynski, J. Stachowiak, G. Hincz, P. 2007. [Administration of natural anthocyanins derived from chokeberry retardation of idiopathic and preeclamptic origin. Influence on metabolism of plasma oxidized lipoproteins: the role of autoantibodies to oxidized low density lipoproteins]. *Ginekologia Polska* **71**:848-53.

1
2 Pawłowicz P, Stachowiak G, Bielak A, Wilczyński J. 2001. [Administration of natural
3 anthocyanins derived from chokeberry (*aronia melanocarpa*) extract in the treatment of
4 oligospermia in males with enhanced autoantibodies to oxidized low density lipoproteins
5 (oLAB). The impact on fructose levels]. *Ginekol Pol* **72**:983-8.
6
7
8
9

10 +48 42/ 271 11 24
11
12

13
14 Pilaczynska-Szczesniak L, Skarpanska-Steinborn A, Deskur E, Basta P, Horoszkiewicz-
15 Hassan M. 2005. The influence of chokeberry juice supplementation on the reduction of
16 oxidative stress resulting from an incremental rowing ergometer exercise. *Int J Sport Nutr*
17 *Exerc Metab* **15**:48-58.
18
19
20
21

22
23
24 Poreba R, Skoczynska A, Gac P, Poreba M, Jedrychowska I, Affelska-Jercha A, Turczyn B,
25 Wojakowska A, Oszmianski J, Andrzejak R. 2009. Drinking of chokeberry juice from the
26 ecological farm Dzieciolowo and distensibility of brachial artery in men with mild
27 hypercholesterolemia. *Ann Agric Environ Med* **16**:305-8.
28
29
30
31

32
33
34 Shellis RP, Addy M, Rees GD.2005. In vitro studies on the effect of sodium tripolyphosphate
35 on the interactions of stain and salivary protein with hydroxyapatite. *J Dent* **33**:313-24.
36
37
38

39
40 Sikora JM, Kostka B, Kozirog-Kolacinska, Choinowska-Jeziarska J, Mikiciuk-Olasik E,
41 Broncel M. 2007. The influence of anthocyanins from *Aronia melanocarpa* on platelet
42 aggregation in patients with metabolic syndrome. www.science24.com/paper/10824
43
44
45
46

47
48 Simeonov SB, Botushanov NP, Karahanian EB, Pavlova MB, Husianitis HK, Troev DM.
49 2002. Effects of *Aronia melanocarpa* juice as part of the dietary regimen in patients with
50 diabetes mellitus. *Folia Med (Plovdiv)* **44**:20-3.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 Skoczynska A, Jedrychowska I, Poreba R, Affelska-Jercha A, Turczyn B, Wojakowska A,
5
6 Andrzejak R. 2007. Influence of chokeberry juice on arterial blood pressure and lipid
7
8 parameters in men with mild hypercholesterolemia. *Pharmacological Reports* **59** Suppl 1:177-
9
10 82.
- 11
12
13
14 Trost K, Golc-Wondra A, Prosek M, Milivojevic L. 2008. Anthocyanin degradation of
15
16 blueberry-*aronia* nectar in glass compared with carton during storage. *J Food Sci* **73**:S405-11.
17
18
19
20 Valcheva-Kuzmanova S, Borisova P, Galunska B, Krasnaliev I, Belcheva A. 2004.
21
22 Hepatoprotective effect of the natural fruit juice from *Aronia melanocarpa* on carbon
23
24 tetrachloride-induced acute liver damage in rats. *Exp Toxicol Pathol* **56**:195-201.
25
26
27
28 Valcheva-Kuzmanova S, Marazova K, Krasnaliev I, Galunska B, Borisova P, Belcheva A.
29
30 2005. Effect of *Aronia melanocarpa* fruit juice on indomethacin-induced gastric mucosal
31
32 damage and oxidative stress in rats. *Exp Toxicol Pathol* **56**:385-92.
33
34
35
36 Valcheva-Kuzmanova SV, Popova PB, Galunska BT, Belcheva A. 2006. Protective effect of
37
38 *Aronia melanocarpa* fruit juice pretreatment in a model of carbon tetrachloride-induced
39
40 hepatotoxicity in rats. *Folia Med (Plovdiv)* **48**:57-62.
41
42
43
44 Valcheva-Kuzmanova S, Kuzmanov K, Tancheva S, Belcheva A. 2007a. Hypoglycemic and
45
46 hypolipidemic effects of *Aronia melanocarpa* fruit juice in streptozotocin-induced diabetic
47
48 rats. *Methods Find Exp Clin Pharmacol* **29**:101-5.
49
50
51
52
53
54
55
56
57
58
59
60

21

1
2 Valcheva-Kuzmanova S, Kuzmanov K, Mihova V, Krasnaliev I, Borisova P, Belcheva A.
3
4 2007b. Antihyperlipidemic effect of *Aronia melanocarpa* fruit juice in rats fed a high-
5
6 cholesterol diet. *Plant Foods Hum Nutr* **62**:19-24.
7
8

9
10 Valcheva-Kuzmanova S, Zhelyazkova-Savova M. 2009. Anxiolytic-like effect of *Aronia*
11
12 *melanocarpa* fruit juice in rats. *Methods Find Exp Clin Pharmacol* **31**:651-4.
13
14

15 Vlachojannis JE, Cameron M, Chrubasik S. 2009. A systematic review on the effectiveness of
16
17 willow bark for musculoskeletal pain. *Phytother Res* **23**: 897-900.
18
19

20
21 Vlachojannis JE, Cameron M, Chrubasik S. 2010a. Medicinal use of potato-derived products :
22
23 a systematic review. *Phytother Res* **24**: 159-62.
24
25

26
27 Vlachojannis JE, Cameron M, Chrubasik S. 2010b. A systematic review on the *Sambucus*
28
29 *fructi* effect and efficacy profiles. *Phytother Res* **24**: 1-8.
30
31

32
33 Wu X, Gu L, Prior RL, McKay S. 2004. Characterization of anthocyanins and
34
35 proanthocyanins in some cultivars of *Ribes*, *Aronia*, and *Sambucus* and their antioxidant
36
37 capacity. *J Agric Food Chem* **52**:7846-56.
38
39

40
41 Yaneva MP, Botushanova AD, Grigorov LA, Kokov JL, Todorova EP, Krachanova MG.
42
43 2002. Evaluation of the immunomodulatory activity of *Aronia* in combination with apple
44
45 (Plovdiv) **44**:22-5.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

22

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Zafra-Stone S, Yasmin T, Bagchi M, Chatterjee A, Vinson JA, Bagchi D. 2007. Berry anthocyanins as novel antioxidants in human health and disease prevention. *Mol Nutr Food Res* **51**:675-83.

Zheng W, Wang SY. 2003. Oxygen radical absorbing capacity of phenolics in blueberries, cranberries, chokeberries, and lingonberries.

For Peer Review

1
2 **Acknowledgement**
3

4 The authors sincerely thank Andrew Black / Bristol for his valuable suggestions during the
5
6 preparation of the manuscript.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review